Kwality Pharmaceuticals Ltd — Important, 10-03-2026: Company Update

Kwality Pharmaceuticals has successfully completed Phase 1 of its Bioequivalence (BE) program, which covers over 30 molecules across key therapeutic areas like Oncology and Cardiology. This phase included successful BE studies for Hydroxycarbamide, Nilotinib, and Liposomal Amphotericin B. The company is now preparing these dossiers for submission in regulated, semi-regulated, and Rest of the World markets. This achievement enhances Kwality Pharmaceuticals' global regulatory presence and supports its goal of broadening access to high-quality pharmaceutical products for stakeholders.